Table 1.
Baseline demographics, clinical characteristics, and laboratory parameters of the study sample.
| Parameters | All patients (n=830) |
Bleeding | P-value | |
|---|---|---|---|---|
| Yes (n=52) | No (n=778) | |||
| Age (years) | 61.1±10.2 | 63.8±12.2 | 60.9±10 | 0.048 |
| Female, n (%) | 222 (26.7) | 15 (28.8) | 207 (26.6) | 0.724 |
| Body mass index, kg/m2 | 28.3±11.6 | 27.9±3.3 | 28.3±12 | 0.826 |
| Systolic blood pressure (mmHg) | 122±19.2 | 120±29.5 | 122±18.3 | 0.439 |
| Diastolic blood pressure (mmHg) | 77.1±15 | 75.8±23.4 | 77.2±14.3 | 0.538 |
| Heart rate (beats/min) | 81.5±12.9 | 84±15.4 | 81.2±12.7 | 0.142 |
| Left ventricular ejection fraction, % | 47.3±9.5 | 41.7±9.5 | 47.8±9.3 | < 0.001 |
| Medical history | ||||
| Hypertension, n (%) | 352 (42.4) | 33 (63.5) | 319 (41) | 0.002 |
| Diabetes mellitus, n (%) | 332 (40) | 27 (51.9) | 305 (39.2) | 0.070 |
| Dyslipidaemia, n (%) | 167 (20.1) | 7 (13.5) | 160 (20.6) | 0.216 |
| Active smoking, n (%) | 316 (38.1) | 16 (30.8) | 300 (38.6) | 0.263 |
| Heart failure, n (%) | 76 (9.2) | 16 (30.8) | 60 (7.7) | < 0.001 |
| Coronary artery disease, n (%) | 229 (27.6) | 21 (40.4) | 208 (26.7) | 0.033 |
| Prior coronary bypass, n (%) | 69 (8.3) | 1 (1.9) | 68 (8.7) | 0.085 |
| Prior PCI, n (%) | 159 (19.2) | 17 (32.7) | 142 (18.3) | 0.010 |
| Alcoholism, n (%) | 107 (12.9) | 13 (25) | 94 (12.1) | 0.007 |
| Stroke, n (%) | 26 (3.1) | 4 (7.7) | 22 (2.8) | 0.051 |
| Renal failure, n (%) | 31 (3.7) | 15 (28.8) | 16 (2.1) | < 0.001 |
| Peptic ulcus, n (%) | 69 (8.3) | 14 (26.9) | 55 (7.1) | < 0.001 |
| Prior bleeding, n (%) | 23 (2.8) | 7 (13.5) | 16 (2.1) | < 0.001 |
| Prior aspirin, n (%) | 194 (23.4) | 19 (36.5) | 175 (22.5) | 0.210 |
| Prior P2Y12 inhibitors, n (%) | 52 (6.2) | 3 (5.7) | 39 (5) | 0.676 |
| Prior NSAİD, n (%) | 154 (18.6) | 18 (34.6) | 136 (17.5) | 0.020 |
| Prior β-blocker, n (%) | 192 (23.1) | 25 (48.1) | 167 (21.5) | < 0.001 |
| Prior RAAS blockers, n (%) | 272 (32.8) | 23 (44.2) | 249 (32) | 0.069 |
| Prior statins, n (%) | 115 (13.9) | 5 (9.6) | 110 (14.1) | 0.361 |
| Laboratory parameters | ||||
| Fasting glucose level, mg/dL | 168.1±83.2 | 186.2±81.6 | 166.9±83.2 | 0.106 |
| White blood cells × 103/µL | 11.6±3.5 | 12±4.2 | 11.5±3.4 | 0.356 |
| Hemoglobin, g/dL | 13.7±1.9 | 12.3±2.0 | 13.9±1.8 | < 0.001 |
| Hematocrit, % | 39.9±5.1 | 36±5.2 | 40.1±5.0 | < 0.001 |
| Platelets, ×103/mL | 264.9±73.2 | 260±93.3 | 265±71.7 | 0.662 |
| Creatinine, mg/dL | 0.8±(0.7-1.0) | 1.2(0.8-1.7) | 0.8 (0.7-0.9) | < 0.001 |
| Urea, mg/dL | 36.6±14.8 | 54.4±27.1 | 35.5±12.7 | < 0.001 |
| eGFR, mL/min | 89.4±21.3 | 64.6±31.3 | 91±19.4 | < 0.001 |
| Sodium, mmol/dL | 137.4±2.8 | 137.1±3.4 | 137.4±2.8 | 0.495 |
| Potassium, mmol/dL | 4.3±0.5 | 4.4±0.5 | 4.3±0.5 | 0.151 |
| Serum uric acid, mg/dL | 5.7±1.6 | 5.9±1.7 | 5.7±1.6 | 0.345 |
| Alanine transaminase, U/L | 24 (18-33) | 27 (18-38) | 24 (17-33) | 0.220 |
| Aspartate aminotransferase, U/L | 32 (23-49) | 33 (26.2-49) | 32 (23-49.3) | 0.450 |
| Albumin, mg/dL | 3.8±0.4 | 3.6±0.4 | 3.8±0.4 | 0.002 |
| NT-proBNP, pg/mL | 775 (256-2230) | 2700 (1253-8070) | 698 (256-2020) | < 0.001 |
| C-reactive protein, mg/L | 5.1 (2.4-11.1) | 7.8 (4.0-12.4) | 5 (2.4-10.9) | 0.028 |
| International normalised ratio | 1±0.13 | 1.02±0.13 | 1.0±0.13 | 0.285 |
eGFR=estimated glomerular filtration rate; NSAID=non-steroidal anti-inflammatory drugs; NT-proBNP=N-terminal pro-B-type natriuretic peptide; PCI=percutaneous coronary intervention; RAAS=renin-angiotensin-aldosterone system